Precipio, Inc. (NASDAQ:PRPO) is reporting third quarter financial results on Thursday 19th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, PRPO is expected to report 3Q20 revenue of $ 2.25 million.
For the full year, analysts anticipate top line of $ 5.62 million.
Previous Quarter Performance
Precipio, Inc. posted loss for the second quarter of $ 0.20 per share, from the revenue of $ 1.31 million. The consensus estimates are loss of $ 0.20 per share from $ 0.90 million in revenue. The top line results outshined analysts by $ 0.41 million or 45.56 percent.
Stock Performance
Shares of Precipio, Inc. traded low $ -0.02 or -0.93 percent on Wednesday, reaching $ 2.13 with volume of 297.70 thousand shares. Precipio, Inc. has traded high as $ 2.14 and has cracked $ 2.08 on the downward trend
According to the previous trading day, closing price of $ 2.13, representing a 290.91 % increase from the 52 week low of $ 0.55 and a 73.13 % decrease over the 52 week high of $ 8.00.
The company has a market capital of $ 36.69 million and is part of the Healthcare sector and Diagnostics & Research industry.
Conference Call
Precipio, Inc. will be hosting a conference call at 5:00 PM eastern time on 19th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, 844-695-5519 (United States) or 1-412-902-6760 Outside U.S. in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.precipiodx.com
Precipio, Inc., a cancer diagnostics company, provides diagnostic products and services to the oncology market. It also develops a platform to eradicate the problem of misdiagnosis within academic institutions. In addition, the company delivers diagnostic information to physicians and their patients.
